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ErbB2 gene amplification occurs in 20%–25% of
breast cancers, and its therapeutic targeting has
markedly improved survival of patients with breast
cancer in the adjuvant setting. However, resistance
to these therapies can develop. Because epigenetic
mechanisms can importantly influence oncogene
expression and be druggable as well, we investi-
gated histone modifications that influence ErbB2
overexpression, independent of gene amplification.
We demonstrate here that ErbB2-overexpressing
breast carcinomas acquire the H3K4me3 mark on
the erbB2 promoter and that receptor-amplified
tumors further acquire the H3K9ac mark, which is
dependent on H3K4me3 mark acquisition. Targeting
WD repeat domain 5 (Wdr5), which is absolutely
required for H3K4me3 enrichment, decreased
ErbB2 overexpression, associated with a decrease
in the H3K4me3 mark on the erbB2 promoter. Of
note, Wdr5 silencing cooperated with trastuzumab
or chemotherapy in specifically inhibiting the growth
of ErbB2-positive breast tumor cells. Thus, our
studies illuminate epigenetic steps in the selection
for ErbB2 activation.
INTRODUCTION
ErbB2 (v-erb-b2 erythroblastic leukemia viral oncogene homo-
log 2; HER2/neu) is a member of the epidermal growth factor re-
ceptor family of receptor tyrosine kinases (Dougall et al., 1994)
andmediates critical signaling functions in normal andmalignant
breast epithelial cells (Yarden and Sliwkowski, 2001). ErbB2
gene amplification, associated with overexpression, occurs in
20%–25% of breast cancers (Slamon et al., 2011) and initially
correlated with an aggressive clinical phenotype, including
high-grade tumors, increased growth rate, early systemic
metastasis, and decreased rate of disease-free and overall sur-
vival (Slamon et al., 1987, 1989). Targeting ErbB2 by trastuzu-302 Cell Reports 5, 302–313, October 31, 2013 ª2013 The Authorsmab or small molecule erbB2 kinase inhibitors (Carter et al.,
1992; Geyer et al., 2006) has markedly improved survival of
such patients in the adjuvant setting (Piccart-Gebhart et al.,
2005; Robert et al., 2006; Slamon et al., 2001). However, the ma-
jority of patients with metastatic breast cancer who initially
respond to trastuzumab develop resistance within 1 year of
treatment initiation, and in the adjuvant setting 15% of patients
still relapse despite trastuzumab-based therapy (Nahta and Es-
teva, 2006). Previous studies have indicated that erbB2-ampli-
fied human breast cancers also exhibit higher expression levels
per gene copy than would be expected (Kraus et al., 1987), as do
erbB2-amplified tumors in a mouse knockin model (Andrechek
et al., 2003), although the mechanistic basis is not yet known.
Cancers show aberrant epigenetic regulation, including global
changes in DNA methylation and altered histone modifications
and histone variants (Arrowsmith et al., 2012; Esteller, 2007; Ro-
drı´guez-Paredes and Esteller, 2011; Vardabasso et al., 2013).
Because epigenetic mechanisms can importantly influence
gene expression (Peltoma¨ki, 2012; Rodrı´guez-Paredes and
Esteller, 2011) and be druggable as well (Arrowsmith et al.,
2012; Delmore et al., 2011; Zuber et al., 2011), we investigated
histone modifications that influence ErbB2 overexpression, in-
dependent of gene amplification. We demonstrate that ErbB2-
overexpressing breast carcinomas acquire the histone H3 lysine
4 trimethylated (H3K4me3) mark on the erbB2 promoter and that
receptor-amplified tumors additionally acquire the H3K9ac
mark. We demonstrate that approaches that interfere with
H3K4me3 mark enrichment on the erbB2 promoter cooperate
with trastuzumab or chemotherapy in specifically inhibiting the
proliferation of ErbB2-positive breast tumor cells. These studies
identify epigenetic mechanisms in addition to the known genetic
alterations that select for increased ErbB2 expression in ErbB2-
positive breast cancers.
RESULTS
ErbB2-Amplified and ErbB2-Overexpressing Cells, but
Not ErbB2-Low Cells, Exhibit H3K4me3 Enrichment on
the erbB2 Promoter
Previous studies have indicated that ErbB2-overexpressing
breast tumor cells exhibit 4- to 8-fold higher and ErbB2-amplified
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breast tumor cells exhibit 64- to 128-fold higher ErbB2 RNA
expression levels than that observed in ErbB2-low breast tumor
cells (Kraus et al., 1987). We analyzed ErbB2-amplified, overex-
pressing breast cancer cells (SkBr3 and BT-474; referred to as
‘‘ErbB2 amplified’’); ErbB2-nonamplified, overexpressing breast
cancer cells (ZR-75-1 and MDA-MB-175 VII; referred to as
‘‘ErbB2-overexpressing’’); and ErbB2 nonamplified, low-ex-
pressing or undetectably expressing breast cancer (MCF-7 and
BT-20) or immortalized human breast epithelial (B5/589) cells
(referred to as ‘‘ErbB2-low’’). We confirmed these overexpres-
sion levels and that the amplified tumor cells exhibited a further
increase in expression per gene copy (Figure 1A; Table S1). In
view of promising new approaches to target epigenetic aberra-
tions in cancer (Arrowsmith et al., 2012; Delmore et al., 2011; Fil-
ippakopoulos et al., 2010; Peltoma¨ki, 2012; Rodrı´guez-Paredes
and Esteller, 2011; Zuber et al., 2011), we tested for local histone
modifications near the erbB2 promoter that might contribute to
increased ErbB2 expression in these tumor cells. We divided
the promoter from516 bp to +67 bp into five regions (Figure 1B)
and studied the relative abundance of histone marks by chro-
matin immunoprecipitation (ChIP) in all of these cells. We identi-
fied the H3K4me3 mark, an established histone mark for active
transcription (Santos-Rosa et al., 2002), in region ‘‘C’’ (304 bp
to221 bp), both in ErbB2-overexpressing and ErbB2-amplified
cells, but not in ErbB2-low cells (Figures 1C and S1A). Glyceral-
dehyde-3-phosphate dehydrogenase (Gapdh) and myogenic
differentiation 1 (MyoD) transcription start sites (TSSs) served
as positive and negative controls for H3K4me3 ChIP analysis
(Figure S2). We did not detect histone H3 lysine 9 trimethylated
(H3K9me3) or histone H3 lysine 27 trimethylated (H3K27me3)
repressive chromatin marks on the erbB2 promoter in any of
these cells (data not shown), indicating the absence of a bivalent
chromatin conformation (Fisher and Fisher, 2011) or evidence
of promoter DNA methylation, even though the erbB2 promoter
has a CpG-rich island (Figures S3A and S3B).
H3K4me3 Enrichment on the erbB2 Promoter Is
Required for ErbB2 Overexpression
The H3K4 methyltransferase complex contains four structural
components (WD repeat domain 5 [Wdr5], RbBP5, Ash2L, and
DPY-30) in addition to a catalytic subunit (Dou et al., 2006; Han
et al., 2006; Steward et al., 2006; Trievel and Shilatifard, 2009).
In agreement with our H3K4me3 ChIP data, we observed
erbB2 promoter occupancy by Wdr5 (Figures 1D and S1B), as
well as by RbBP5 (Figures 1E and S1C) and Ash2L (Figures 1F
and S1D), in ErbB2-overexpressing and ErbB2-amplified cells,
but not in ErbB2-low cells. Gapdh TSS and MyoD TSS wereFigure 1. H3K4me3, Wdr5, RbBP5, and Ash2L Are Specifically Recrui
Amplified Tumor Cells
(A) Western blot analysis showing the ErbB2 protein expression across the cell l
(B) Schematic representation of the erbB2 promoter, showingmajor andminor TS
for chromatin immunoprecipitation (ChIP) are also indicated.
(C–F) ChIP analysis showing the H3K4me3 enrichment (C) and occupancy ofWdr5
1, and SkBr3 cells. The relative H3K4me3 enrichment or occupancy each prote
promoter, which shows themost significant difference between different cell types
controls, respectively, in each ChIP experiment (Figure S2). The error bars repre
three times, and representative experimental data are shown.
See also Figures S1 and S2.
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(Figure S2). Wdr5 is a WD40 repeat protein, which functions to
target dimethylated H3K4 (H3K4me2) for H3K4 trimethylation
(H3K4me3) (Dou et al., 2005; Patel et al., 2009; Wysocka et al.,
2005). Recent in vitro studies also have indicated that Wdr5 is
unable to discriminate between H3K4 methylation states
(Couture et al., 2006; Ruthenburg et al., 2006). However,
H3K4me3 enrichment is absolutely correlated with Wdr5 pro-
moter occupancy (Dou et al., 2006; Patel et al., 2009), and loss
of Wdr5 affects global H3K4 trimethylation in vivo (Ang et al.,
2011; Wysocka et al., 2005).
To analyze the role ofWdr5 in ErbB2 expression, we generated
B5/589, ZR-75-1, and SkBr3 cells stably expressing doxycy-
cline-inducible Wdr5 small hairpin RNA (shRNA). Doxycycline-
inducible GFP shRNA was used as a negative control in all
shRNA experiments to test for off-target effects of doxycycline
and nonspecific shRNA effects. Addition of doxycycline to the
culture medium led to a decrease in Wdr5 expression in
shWdr5-expressing cells, but not in shGFP-expressing cells,
as measured at mRNA (Figures 2A and 2C) and protein (Figures
2B, 2D, and S4A) levels, resulting in reduced H3K4me3 enrich-
ment on the erbB2 promoter both in ErbB2-overexpressing
(ZR-75-1) and erbB2-amplified (SkBr3) cells (Figures S4B and
S4C). Downregulation of Wdr5 specifically induced in each
case reduced ErbB2 expression as measured at both mRNA
(Figures 2A and 2C) and protein (Figures 2B and 2D) levels. To
further confirm the specificity of the Wdr5 shRNA, we generated
SkBr3 cells stably overexpressing Wdr5 open reading frame
(ORF) in the background of inducible Wdr5 silencing. Whereas
shWdr5 sequence 1 targets the Wdr5-ORF, shWdr5 sequence
2 targets the 30 UTR. In SkBr3 vector control cells, doxycycline
induction of shWdr5-Seq 1 or shWdr5-Seq 2 reduced endoge-
nous Wdr5 mRNA and protein levels (Figures S5A and S5B;
data not shown). As expected, in SkBr3 cells overexpressing
Wdr5-ORF, doxycycline induction reduced Wdr5 levels in
shWdr5-Seq 1-, but not in shWdr5-Seq 2-expressing cells. Of
note, Wdr5-ORF overexpression was able to rescue ErbB2
expression in doxycycline-induced SkBr3-shWdr5-Seq 2-ex-
pressing cells (Figures S5A and S5B), but not in SkBr2-shWdr-
Seq 1-expressing cells (data not shown). Further, releasing the
cells from Wdr5 silencing by removing doxycycline from the cul-
ture medium resulted in restoration of Wdr5 expression and
ErbB2 re-expression (Figure S5C). All of these results estab-
lished the functional involvement of Wdr5 in increased ErbB2
expression.
Because Wdr5 has been shown to be involved in multiple
histone methyltransferase (HMT) as well as histoneted onto the erbB2 Promoter in ErbB2-Overexpressing and ErbB2-
ines.
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(A–D) Real–time quantitative PCR (A and C) and western blot analysis (B and D) of ZR-75-1 (A and B) and SkBr3 (C and D) cells stably transduced with inducible
shRNA viruses and cultured in the presence of doxycycline for 48 hr.
(E) Schematic representation of the erbB2 promoter, showing major and minor TSS and the translational start site. The five regions used for chromatin immu-
noprecipitation (ChIP) are also indicated. The AP-2 binding site along with the recognition sequence is shown.
(F) ChIP analysis showing the AP-2 occupancy on the erbB2 promoter in B5/589, MCF-7, ZR-75-1, and SkBr3 cells. The target sequences (corresponding to
region ‘‘C’’) were detected by quantitative real-time PCR analysis of eluted DNA. The relative occupancy of AP-2 over the % input is shown in the form of a bar
diagram.
(legend continued on next page)
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acetyltransferase (HAT) complexes (Dou et al., 2005; Thompson
et al., 2008), it is possible that Wdr5 knockdown affects not only
H3K4 trimethylation but also other chromatin remodeling events,
which might contribute to decreased ErbB2 expression. In
contrast to Wdr5, Ash2L has been shown to be a specific
component of an MLL (mixed lineage leukemia) complex, and
Ash2L reduction leads to specific loss of H3K4me3, without
altering the levels of either Wdr5 or H3K4me1 and H3K4me2
(Steward et al., 2006). To confirm the role of H3K4me3 enrich-
ment in ErbB2 expression, we measured ErbB2 levels in cells
specifically silenced for Ash2L utilizing SkBr3 cells stably ex-
pressing doxycycline-inducible Ash2L shRNA. Addition of doxy-
cycline to the culture medium resulted in decreased Ash2L
expression as measured at both mRNA (Figure S6A) and protein
(Figure S6B) levels and also reduced H3K4me3 enrichment on
the erbB2 promoter (Figure S6C). In addition, downregulation
of Ash2L was associated in each case with reduced ErbB2
expression as measured at both mRNA (Figure S6A) and protein
(Figure S6B) levels. These results establish that H3K4me3
enrichment by anMLL complex observed on the erbB2 promoter
is essential for increased ErbB2 expression.
H3K4me3 Enrichment Enables AP-2 Recruitment on the
erbB2 Promoter
Wenext sought todeterminewhetherH3K4me3enrichment influ-
ences recruitment to the erbB2 promoter of transcription factors
that are known to regulate ErbB2 expression. The activator pro-
tein-2 (AP-2) binding site on the erbB2 promoter was mapped
to a region 217 bp upstream of the erbB2 TSS (Bosher et al.,
1995). Moreover, this site was immediately adjacent to region
‘‘C’’ of the erbB2 promoter, which was positive for H3K4me3
and its readers (Figure 2E). Confirming previous findings (Bosher
et al., 1995), ChIP analysis showed that AP-2 exhibited increased
occupancy on the erbB2 promoter in overexpressing and ampli-
fied tumors as compared to ErbB2-low cells (Figure 2F). Further,
we observed reduced AP-2 promoter occupancy in response to
Wdr5 silencing in both ErbB2-overexpressing (Figure 2G) and
ErbB2-amplified cells (Figure 2H), without detectable changes
in the total cellular AP-2 levels (Figures 2B and 2D). In contrast,
we observed no differences in AP-2 promoter occupancy on
the BCl-2 promoter, another well-established AP-2 target gene
(Wajapeyee et al., 2006), across the cell lines tested (Figure S7A).
Further, silencing Wdr5 did not affect AP-2 occupancy on the
BCl-2 promoter (Figure S7B), even though it reduced H3K4me3
enrichment on the BCl-2 TSS (Figure S7C). Taken together, these
results indicate thatWdr5 recruitment facilitatesH3K4me3,which
in turn favorsAP-2occupancyspecificallyon theerbB2promoter.
The erbB2 Promoter Is H3K9 Acetylated in
erbB2-Amplified, but Not in ErbB2-Overexpressing and
ErbB2-Low, Breast Tumor Cells
Previous studies have indicated that erbB2-amplified breast tu-
mor lines express more transcripts per gene copy than would be(G and H) ChIP analysis showing AP-2 occupancy on erbB2 promoter in ZR-75-1
cultured in the presence of doxycycline for 48 hr. The target sequences (corresp
eluted DNA. The relative AP-2 promoter occupancy over the % input is shown in t
repeated at least three times, and representative experimental data are shown.
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(Kraus et al., 1987). We confirmed these findings with ZR-75-1
cells, which showed a 4-fold increase in expression of ErbB2
compared to ErbB2-lowMCF-7 cells. SkBr3 cells, which showed
4- to 8-fold gene amplification, overexpressed ErbB2 128-fold,
rather than the expected 16- to 32-fold, compared to MCF-7
cells (Kraus et al., 1987) (Figure 1A; Table S1; Figures S11A
and S11B). This discrepancy between predicted and actual
levels of ErbB2 overexpression with gene amplification has
been observed also in the Neu knockin mouse model, in which
transcriptional upregulation of Neu mRNA is greater than can
be accounted for by the 2- to 20-fold amplification of the acti-
vated neu allele (Andrechek et al., 2003). Thus, we reasoned
that there might be additional promoter chromatin modifications
in erbB2-amplified breast tumors. In fact, we observed histone
H3 lysine 9 acetylation (H3K9ac) in ErbB2-amplified, but not in
ErbB2-overexpressing or ErbB2-low cells (Figures 3A and
S8A). Gapdh TSS, MyoD TSS, and ALDOA TSS were used as
positive and negative controls for H3K9ac ChIP assays. Note
that ALDOA (aldolase A) TSS was positive for H3K4me3 and
negative for the H3K9ac histone mark (Figure S2). This modifica-
tion had functional significance, shown by treatment with
anacardic acid, a known HAT inhibitor (Mai et al., 2006;
Rodrı´guez-Paredes and Esteller, 2011), which reduced ErbB2
expression levels specifically in erbB2-amplified cells but had
no detectable effect on ErbB2-overexpressing, nonamplified
cells as measured at both mRNA (Figure 3B) and protein (Fig-
ure 3C) levels.
Gcn5MediatesH3K9Acetylation on the erbB2Promoter
in erbB2-Amplified Breast Tumor Cells
Anacardic acid has been shown to inhibit the activities of several
HATs, including p300, PCAF, Tip60, and Gcn5 (Hemshekhar
et al., 2011). The H3K9ac mark is written by PCAF or Gcn5 (Kou-
zarides, 2007), each of which has distinct as well as overlapping
functions (Xu et al., 2000). Further, Gcn5-mediated H3K9ac is
thought to recruit additional transcription factors leading to the
formation of a more efficient transcription preinitiation complex
(Koutelou et al., 2010). To identify the HAT responsible for
H3K9 acetylation on the erbB2 promoter, we generated stable
cell lines expressing either doxycycline-inducible shPCAF or
shGcn5. Addition of doxycycline to the culture medium reduced
PCAF expression levels in SkBr3 cells as measured at both
mRNA and protein (Figures S9A and S9B) levels, using two
different shRNA constructs. However, PCAF silencing had no
significant effect on ErbB2 expression as measured at both
mRNA and protein (Figures S9A and S9B) levels. Next, we gener-
ated stable cell lines expressing doxycycline-inducible shGcn5
in both ErbB2-overexpressing ZR-75-1 and erbB2-amplified
SkBr3 breast tumor cells. Addition of doxycycline to the culture
medium reduced Gcn5 expression levels in each breast tumor
line at both mRNA (Figures 3D and 3F) and protein (Figures 3E
and 3G) levels, using two different shRNA constructs. Of note,(G) or in SkBr3 (H) cells that were stably transduced with sh-Wdr5 (Seq 1) and
onding to region ‘‘C’’) were detected by quantitative real-time PCR analysis of
he form of a bar diagram. The error bars represent SEM. Each experiment was
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Figure 3. The erbB2 Promoter Is H3K9 Acetylated by Gcn5 in ErbB2-Amplified Cancers Only and Not in ErbB2-Overexpressing or ErbB2-Low
Cells
(A) ChIP analysis showing the H3K9ac enrichment on the erbB2 promoter in B5/589, MCF-7, ZR-75-1 and SkBr3 cells. The relative H3K9ac enrichment over the
% input is shown in the form of a bar diagram. Gapdh TSS,MyoD TSS and ALDOA TSSwere used as positive and negative controls for H3K9ac ChIP assays. Note
that ALDOA (aldolase A) TSS was positive for H3K4me3 and negative for H3K9ac histone mark (Figure S2).
(B and C) Quantitative real-time PCR (B) and western blot (C) analysis showing ErbB2 expression in the indicated cancer cell lines treated with either 0, 100, or
200 mM anacardic acid for 24 hr.
(legend continued on next page)
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Gcn5 silencing reduced ErbB2 mRNA expression specifically in
erbB2-amplified tumor cells (Figures 3D and 3F), which corre-
lated well with reduced protein levels (Figures 3E and 3G) and
loss of H3K9ac on the erbB2 promoter following doxycycline
treatment (Figure S8B). All of these findings indicate that
Gcn5-mediated H3K9ac, but not PCAF-mediated H3K9ac,
was responsible for the expression of more transcripts per given
gene copy in erbB2-amplified compared to ErbB2-overexpress-
ing tumor lines.
We observed that Gcn5 was recruited onto the erbB2 pro-
moter in erbB2-amplified cells, but not in either ErbB2-low or in
ErbB2-overexpressing cells (Figure S8C). Further, in Gcn5-
silenced cells, there was no detectable change in H3K4me3
enrichment (Figure S8D) or in AP-2 promoter occupancy (Fig-
ure S8E). In contrast, Wdr5 silencing resulted in reduced
H3K9ac enrichment on the erbB2 promoter in SkBr3 cells (Fig-
ure S10). These findings argue strongly that H3K9ac enrichment
on the erbB2 promoter in ErbB2-amplified breast cancers re-
quires the presence of the H3K4me3 mark.
Validation of Histone PTMs in ErbB2-Positive Breast
Tumor Tissues
Wenext sought to confirm the presence of the histone posttrans-
lational modifications (PTMs) identified in ErbB2-overexpressing
and erbB2-amplified breast tumor lines in primary human breast
cancer tissues. ChIP analysis with H3K4me3- and H3K9ac-
recognizing antibodies revealed that ErbB2-overexpressing,
nonamplified primary tumors showed the H3K4me3 mark, but
not the H3K9ac mark, whereas erbB2-amplified tumor samples
exhibited both marks on the erbB2 promoter (Figures 4A and
S11A). In contrast, tissue samples from ErbB2-low breast cancer
patients showed neither of these histone modifications on the
erbB2 promoter (Figures 4A and S11A). In each case, the enrich-
ment of these histone marks correlated with the ErbB2 mRNA
expression levels (Figure S11B). Thus, the histone marks
observed in primary breast tumors reflected those we identified
in ErbB2-positive breast tumor cell lines.
ErbB2 and Grb7 Exhibit Different Mechanisms of
Overexpression, Even Though They AreCoamplified and
Coexpressed
Growth factor receptor bound protein-7 (Grb7) gene is
commonly coamplified and overexpressed with ErbB2 in breast
cancer lines and primary tumors (Stein et al., 1994). Grb7 has
been shown to physically interact with ErbB2 and to enhance
its signaling functions (Nadler et al., 2010; Stein et al., 1994) as
well as those of several other tyrosine kinases through its SH2
domain (Pero et al., 2003). Moreover, Grb7 has been reported
to contribute to tumorigenesis by the erbB2 oncogene in mouse
models (Kao and Pollack, 2006). Grb7 was not overexpressed in
ErbB2-overexpressing, nonamplified tumor cells (data not
shown), in agreement with recent studies (Ramsey et al.,(D–G) Quantitative real-time PCR (D and F) and western blot (E and G) analysis of
shRNA viruses and cultured in the presence of doxycycline for 48 hr. Doxycycline-
to test for off-target effects of doxycycline and nonspecific shRNA effects. The err
representative experimental data areshown.
See also Figure S2.
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did not alter Grb7 expression levels as measured at both
mRNA (data not shown) and protein (Figure S12) levels. These
findings argue that Grb7 does not utilize these same epigenetic
mechanisms to upregulate its transcription.
Effects of Targeting Epigenetic Proteins On
Chemotherapy- and Trastuzumab-Induced Breast Cell
Growth Inhibition
Next, we investigated the functional consequences of Wdr5
silencing on breast tumor cell growth. Wdr5 silencing reduced
cell growth in both ErbB2-overexpressing and ErbB2-amplified
tumor cells, but had no detectable effect on ErbB2-low immortal-
ized breast epithelial cells (Figure 4B).Moreover,Wdr5 presilenc-
ing enhanced the sensitivity of both ErbB2-overexpressing and
erbB2-amplified, but not ErbB2-low, immortalized breast cancer
cells to cisplatin, a chemotherapy agent used in breast and
ovarian cancer therapy (Pegram et al., 1999) (Figure 4C). Trastu-
zumab, a humanized ErbB2-targeting antibody that has been
shown to improve progression-free survival and overall survival
in breast cancer patients with erbB2 amplification (Paik et al.,
2008), reduced viability of ErbB2-amplified tumor cells in a
dose-dependentmanner (Figure 4D). It had amoremodest effect
on viability of ErbB2-overexpressing cells and no effect on
ErbB2-low immortalized breast epithelial cells (Figure 4D). Presi-
lencing of Wdr5 in combination with trastuzumab also did not
affect the viability of ErbB2-low immortalized breast epithelial
cells (Figure 4D), whereas Wdr5 presilencing enhanced the
growth inhibitory effect of trastuzumab in erbB2-amplified cells
(Figure 4D). Compared to erbB2-amplified tumor cells, ErbB2-
overexpressing cells responded only modestly to trastuzumab
as a single agent, but showed significantly greater growth
inhibition in combination with Wrd5 presilencing as measured
in short-term culture byMTT (3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide) assay (Figure 4D) or longer term by
soft agar assay (Figure S13). These results suggest that trastuzu-
mab in combination with Wdr5 targeting may be a promising
therapeutic approach for patients with ErbB2-overexpressing
breast cancer cells and potentially for ErbB2-positive breast can-
cers that become resistant to conventional targeted therapies.
DISCUSSION
Transgenic targeting of the overexpressed wild-type erbB2 gene
in the mouse mammary gland has been shown to select for
mammary tumors with ErbB2 overexpression and the well-char-
acterized neumutation (Guy et al., 1992). Similarly, knocking in of
themutant form under control of the endogenous promoter leads
to mammary tumors that also overexpress and amplify this gene
(Andrechek et al., 2003), indicating in each case a stepwise se-
lection for greater ErbB2 expression/activity. In humans, analo-
gous mutations of the erbB2 gene are generally not observed.ZR-75-1 (D and E) and SkBr3 (F and G) cells stably transduced with inducible
inducible GFP shRNAwas used as a negative control in all shRNA experiments
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However, different levels of overexpression and of gene amplifi-
cation/overexpression have been reported among human
ErbB2-positive tumors. In the present study, we elucidated
epigenetic modifications that accumulate on the erbB2 pro-
moter, leading to increased expression of this proto-oncogene.
AP-2 is highly expressed in breast cancer cell lines overexpress-
ing ErbB2 and positively regulates ErbB2 expression (Bosher
et al., 1995, 1996; Grooteclaes et al., 1999). We showed that
H3K4me3 enrichment on the erbB2 promoter is responsible for
enhanced AP-2 promoter occupancy and elevated ErbB2
expression. Our findings that the H3K4me3 mark is common to
both tumor subsets indicate that overexpression and amplifica-
tion are epigenetically linked. Moreover, our evidence that in
erbB2 receptor-amplified tumors H3K9ac specifically accumu-
lates on the erbB2 promoter associated with further enhance-
ment of expression per gene copy is consistent with this mark
occurring as the result of continued epigenetic selective pres-
sure (Figure 4E). These newly observed epigenetic alterations
take place in the context also of amplification/overexpression
of Grb7, an oncogene shown here to be under independent
epigenetic control. Thus, erbB2 activation in human breast can-
cers can involve a number of discrete epigenetic as well as ge-
netic alterations (Andrechek et al., 2000; Di Fiore et al., 1987;
Muller et al., 1988).
MLL complexes have been shown to methylate H3K4, and
Wdr5 is a conserved subunit of these complexes and has been
shown to be required to maintain MLL complex integrity (Stew-
ard et al., 2006). Although Wdr5 has been reported not to
discriminate mono-, di-, tri-, or unmethylated H3K4 positions
(Couture et al., 2006; Ruthenburg et al., 2006), it affects global tri-
methylation at the same residue (Dou et al., 2006;Wysocka et al.,
2005). In contrast to Wdr5, Ash2L is a specific component of
H3K4me3 methyl transferase complex, and its reduction led to
specific loss of H3K4me3 (Steward et al., 2006). In the present
study, silencing of either Wdr5 or Ash2L abrogated H3K4me3
enrichment on the erbB2 promoter and interfered with ErbB2
expression, establishing that this histone mark enrichment plays
a major role in enhancing erbB2 expression in erbB2 positive
breast tumor cells.
Human Gcn5 is part of the large SAGA (Spt-Ada-Gcn5 acetyl
transferase) complex, which enforces gene expression patterns
by acetylating histones (Koutelou et al., 2010; Rodrı´guez-Nav-
arro, 2009). We detected H3K9ac on the erbB2 promoter only
in amplified tumors. Moreover, Gcn5 silencing reduced
H3K9ac without affecting the H3K4me3 enrichment, observed
in all ErbB2 positive tumors. In contrast, silencing Wdr5 reducedFigure 4. Wdr5 Silencing Cooperates with Chemotherapy- and Trastuz
(A) ChIP analysis showing H3K4me3 and H3K9ac enrichment on the erbB2 prom
patients. The relative H3K4me3 and H3K9ac enrichment over the % input is sho
(B) Cell growth of the indicated cell lines with or without doxycycline (to induce W
(C and D) Cell viability of the indicated cells in the absence and presence of doxyc
error bars represent SEM. Each experiment (except A: patient ChIPs; done once
shown. The statistical significancewas calculated by Student’s t test inMS Excel u
is indicated by two asterisks.
(E) Schematic model showing the regulation of chromatin conformation on the er
ErbB2-amplified/overexpressing cancers, the promoter is H3K4 trimethylated,
transcription factor, leading to ErbB2 transcription. In ErbB2-amplified/overexpres
transcriptional enhancement. The proteins illustrated in green were specifically o
310 Cell Reports 5, 302–313, October 31, 2013 ª2013 The Authorsboth H3K4me3 and H3K9ac marks on the erbB2 promoter in
erbB2-amplified tumor cells, arguing strongly that H3K9ac
enrichment requires the presence of H3K4me3 mark. All these
findings support the concept that ErbB2-overexpression/ampli-
fication occurs in a stepwise manner, in which ErbB2 over-
expression precedes erbB2-amplification. Whether H3K9ac
enrichment arises following gene amplification or proceeds
and selects for gene amplification is not known.
Recent evidence indicates that some ErbB2-overexpressing
breast tumors in the absence of gene amplification respond
clinically to trastuzumab (Paik et al., 2008), and a major phase
3 clinical trial has been initiated to evaluate the efficacy of trastu-
zumab in combination with chemotherapy in women with breast
cancers designated as HER2 overexpressed but nonamplified
(as determined by all HER2 tests performed) (National Surgical
Adjuvant Breast and Bowel Project NSABP-B-47;
NCT01275677). Thus, it would be of interest to determine
whether a subset of such tumors exhibit the H3K9acmark, asso-
ciated with high levels of ErbB2 expression and better clinical
response to trastuzumab.
Cancer epigenetics has achieved the oncology mainstream,
with epigenetic drug discovery showing promise in therapy
(Esteller, 2007, 2008; Filippakopoulos et al., 2010; Rodrı´guez-
Paredes and Esteller, 2011). Resistance to trastuzumab can
develop via multiple mechanisms, including modification of the
antibody binding site (Nahta and Esteva, 2006). Lapatinib, a
small-molecule inhibitor of ErbB2 tyrosine kinase activity, is a
newer ErbB2-targeting drug (Geyer et al., 2006) but can lead to
acquired resistance via mutation in the erbB2 kinase domain
(Kancha et al., 2011). In short-term culture, Wdr5 knockdown
did not affect ErbB2-low cell proliferation or cooperate with
chemotherapy. In contrast, ErbB2 nonamplified overexpressing
cells showed little or no growth inhibition with trastuzumab
alone, but the combination of trastuzumab with targeting Wdr5
expression strongly inhibited colony formation in soft agar.
Although the long-term effects of Wdr5 silencing need to be
further explored, it is possible that agents that inhibit H3K4me3
enrichment, identified by us as playing a major role in upregulat-
ing erbB2 transcription, may one day be applicable in targeting
ErbB2-positive breast tumors.EXPERIMENTAL PROCEDURES
Patient Samples and Gene Copy Number Verification
Tissues were received from the NCI Cooperative Human Tissue Network. Use
of anonymized human tissues was approved by Mount Sinai’s institutionalumab-Induced Growth Inhibition
oter in breast cancer patient samples, where P1 through P14 indicate different
wn in the form of a bar diagram. See also Figure S11.
dr5-shRNA) in the culture medium.
ycline and with increasing doses of either Cisplatin (C) or trastuzumab (D). The
) was repeated at least three times, and representative experimental data are
sing two-tailed analysis. A p value <0.005 is indicated by one star, and <0.0005
bB2 promoter in different cancers. In ErbB2-nonamplified/overexpressing and
which opens chromatin structure and facilitates the recruitment of the AP-2
sing cancers only, Gcn5 causes H3K9 acetylation, which further promotes this
bserved by ChIP in this study to occupy the erbB2 promoter.
review board. Gene copy number was analyzed by genomic PCR spanning
intron-exon junctions. b-Globin gene was used as internal control. Please
see Table S2 for the sequence of primers used.
Cell Lines, Plasmids, and Treatments
B5/589, MCF-7, and BT-20 (ErbB2-low expressing), ZR-75-1 and MDA-MB-
175 VII (ErbB2-overexpressing but nonamplified), and BT-474 and SkBr3
(ErbB2-overexpressing and amplified) breast cancer cells were used. Specific
gene silencing was achieved by using either pTripZ (Open Biosystems) or Tet-
pLKO-puro (Addgene #21915) vectors. Human Wdr5 ORF was PCR amplified
and cloned into pCDNA3 using EcoRI and XhoI enzymes. Trastuzumab,
obtained from Genentech (#NDC 50242-056-56), was provided by Dr. George
Raptis (Mount Sinai Medical Center).
Real-Time Quantitative PCR and Western Blotting
RNA extraction and quantitative real-time PCR was performed as described
previously (Mungamuri et al., 2012). Western blotting was performed as
described previously (Mungamuri et al., 2006), with the exception that Alexa
Fluor secondary antibodies were used. All blots were developed using the
Odyssey fluorescence image scanner, and the band intensities were quanti-
fied using LI-COR software. Please see Table S2 for the sequences of primers
used.
Quantitative ChIP PCR Assay
ChIP assay was performed as described previously (Mungamuri et al., 2012).
Quantitative real-time PCR was performed on the eluted DNA to identify the
amount of target sequence. Please see Table S2 for the sequences of primers
used.
Generation of Stable Cell Lines
B5/589, ZR-75-1, and SkBr3 cells were infected either with pTripZ:sh-GFP,
pTripZ:sh-Wdr5, pTripZ:sh-Gcn5, Tet-pLKO-shGFP, Tet-pLKO-shAsh2L, or
with Tet-pLKO-shPCAF lentivirus and selected for puromycin (2 mgml1) resis-
tance. Stable puromycin-resistant clones were pooled to generate doxycy-
cline-inducible shRNA cell lines. The shRNA expression was induced with
1 mg ml1 doxycycline for 48 hr.
MTT Assay
The MTT assay, which measures the conversion of the MTT tetrazolium salt
into blue formazan crystals by living cells, was performed as described previ-
ously (Mungamuri et al., 2006).
Anchorage-Independent Growth by Colony Formation in Soft Agar
SkBr3 and ZR-75-1 cells stably expressing inducible shWdr5 were plated for
soft agar assay. Base agar was prepared by mixing 0.8 ml of 3% agar to
4.2 ml of complete medium (final agar concentration 0.6%) and 1 ml was
added to each 35 mm dish in triplicate. After the base agar is set, 3% agar
solution was mixed with 2 3 104 cells in medium (final agar concentration
0.34%) and layered on the solidified base agar. For shRNA induction,
1 mg ml1 doxycycline was added to complete medium and 200 ml of fresh
medium with doxycycline was overlaid every alternative day. The plates
were incubated at 37C for up to 3 weeks. Colonies were counted and
microphotographed.
For further details, please refer to the Extended Experimental Procedures.
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